ABOUT VHIO

VHIO is a leading comprehensive cancer center of excellence where its scientists and physicians adopt a purely translational research model, working together as multidisciplinary teams to both accelerate and advance personalized and targeted therapies against cancer:

DISCOVER MORE

PROGRAMS & GROUPS

Scientific activity at VHIO is structured across for major programs: Preclinical, Translational, Clinical Research, and Core Technologies. Each incorporates research teams of excellence dedicated to harnessing and rapidly translating discoveries into tangible benefits for patients.

MEET VHIO´S TEAMS

NEWS

VHIO researchers describe the relevance of molecular selection in a new era of clinical trials

07/07/2020|Comments Off on VHIO researchers describe the relevance of molecular selection in a new era of clinical trials

Seven European centers develop a web-based decision-making support tool for oncologist to improve treatment selection

06/07/2020|Comments Off on Seven European centers develop a web-based decision-making support tool for oncologist to improve treatment selection

Vall d’Hebron takes part in the development of the first effective drug for a subtype of GIST orphan of treatment

30/06/2020|Comments Off on Vall d’Hebron takes part in the development of the first effective drug for a subtype of GIST orphan of treatment

  • Dr. Josep Tabernero - No tractem malalties
  • Dr. Josep Tabenero - Objetivo
  • Carrusel Dr. Josep Tabernero

VHIO’s director, Josep Tabernero, awarded the National Research Award 2019

29/06/2020|Comments Off on VHIO’s director, Josep Tabernero, awarded the National Research Award 2019

Vall d’Hebron identifies a prognostic marker of rectal cancer based on gut microbiome

23/06/2020|Comments Off on Vall d’Hebron identifies a prognostic marker of rectal cancer based on gut microbiome

Vall d’Hebron takes part in a study demonstrating the efficacy ofa new drug in patients with advanced GIST

05/06/2020|Comments Off on Vall d’Hebron takes part in a study demonstrating the efficacy ofa new drug in patients with advanced GIST

SEE ALL NEWS

Follow us:

DIRECTION &
PRINCIPAL INVESTIGATORS

Research at VHIO is led by our Director, Josep Tabernero, and supported by a consultative body, VHIO’s Scientific Committee. A total of 26 renowned Principal Investigators manage and run VHIO’s major research themes and programs.

BROWSE OUR PIS

SCIENTIFIC
REPORT
2018

LAUNCH

CLINICAL TRIALS

Driving drug development & targeted therapies against cancer, VHIO has become a leading reference in drug discovery from concept to clinic:

CLINICAL TRIALS OFFICE
RESEARCH UNIT FOR MOLECULAR THERAPY OF CANCER – “LA CAIXA”
CURRENTLY OPEN TRIALS

PROJECTS & INSTITUTIONAL PROGRAMS

Research at VHIO is made possible through the support received from private institutions, funding entities, companies and individuals, as well as International and National Competitive Grants. Find out more about our supporters, current projects and VHIO´s Scientific Coordination Area:

CURRENT PROJECTS
FERO FOUNDATION’S ADVANCED MOLECULAR DIAGNOSTICS PROGRAM
BBVA FOUNDATION’S IMMUNOTHERAPY & IMMUNOLOGY PROGRAM (CAIMI)
“LA CAIXA” INTL RESEARCH & EDUCATION PROGRAM
SCIENTIFIC COORDINATION

EVENTS

VHIO organizes symposia of excellence and ad-hoc courses & workshops through which it shares its expertise and promotes debate and exchange of the highest degree:

VHIO – ”LA CAIXA” SCIENTIFIC SEMINARS SERIES
INTERNATIONAL SYMPOSIA
WORKSHOPS & COURSES
BENCHSTORMING SEMINARS